ClinicalTrials.gg
CompletedNCT06683352Updated Aug 19, 2026Results posted

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

A Phase 1/2 interventional study of Investigational Influenza Vaccine and COVID-19 Vaccine in Influenza,Human and COVID-19, sponsored by BioNTech SE. Completed at 22 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Enrollment
169th of 843
1,353 · median 270
Started
2024
with 34 others
Phase 1/2
72 of 966
1 open now
Registered
907th of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 169th largest by enrollment of the 843 interventional ones that give a count, is one of 35 that started in 2024, is one of 72 in phase 1/2, and was the 907th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.

03

Conditions studied

  • Influenza,Human
  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 18 years of age or older
  • Healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Vaccination with any or licensed 2024-2025 season formulation influenza or COVID-19 vaccine.
  • Treated with antiviral therapies for influenza (eg, Tamiflu) within 180 days prior to Day 1

Please refer to the study contact for further eligibility details.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,353 participants (actual)

Study arms

  • Experimental
    Arm A/AA

    Low Dose COVID-19 Vaccine and Placebo

    Biological: COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm B/BB

    Medium Dose COVID-19 Vaccine and Placebo

    Biological: COVID-19 Vaccine · Other: Placebo

  • Active comparator
    Arm C/CC

    High Dose COVID-19 Vaccine and Placebo

    Biological: COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm D/DD

    Low Dose Investigational Influenza Vaccine and Placebo

    Biological: Investigational Influenza Vaccine · Other: Placebo

  • Active comparator
    Arm E

    Licensed Influenza Vaccine 1 and Licensed COVID-19 Vaccine

    Biological: COVID-19 Vaccine · Biological: Licensed Influenza Vaccine 1

  • Active comparator
    Arm EE

    Licensed Influenza Vaccine 2 and Licensed COVID-19 Vaccine

    Biological: COVID-19 Vaccine · Biological: Licensed Influenza Vaccine 2

  • Experimental
    Arm F/FF

    Medium Dose Investigational Influenza Vaccine and Placebo

    Biological: Investigational Influenza Vaccine · Other: Placebo

  • Experimental
    Arm G/GG

    Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo

    Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm H/HH

    Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine and Placebo

    Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm I/II

    Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo

    Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm J/JJ

    High Dose Investigational Influenza Vaccine and Placebo

    Biological: Investigational Influenza Vaccine · Other: Placebo

  • Experimental
    Arm K/KK

    Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo

    Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm L/LL

    Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo

    Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm M/MM

    High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo

    Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo

  • Experimental
    Arm N

    High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo

    Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo

Interventions

  • BiologicalInvestigational Influenza Vaccine

    Investigational Influenza Vaccine

  • BiologicalCOVID-19 Vaccine

    Pfizer-BioNTech COVID-19 Vaccine

  • Combination productInvestigational Influenza/COVID-19 Vaccine

    Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine

  • BiologicalLicensed Influenza Vaccine 1

    Licensed Influenza Vaccine 1

  • BiologicalLicensed Influenza Vaccine 2

    Licensed Influenza Vaccine 2

  • OtherPlacebo

    Saline

06

What researchers measure

Primary outcomes

  1. Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination

    Local reactions included redness, swelling, and pain at the injection site, were recorded in the electronic dairy (e-diary) or case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]

  2. Cohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination

    Local reactions included redness, swelling, and pain at the injection site, were recorded in the e-diary or CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]

  3. Cohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination

    Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]

  4. Cohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination

    Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]

  5. Cohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. Serious AE (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.

    Time frame: From Vaccination on Day 1 through 1 month after Vaccination [Vaccination on Day 1]

  6. Cohort 2: Percentage of Participants Reporting AEs From Vaccination Through 1 Month After Vaccination

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.

    Time frame: From Vaccination on Day 1 through 1 month after Vaccination [Vaccination on Day 1]

  7. Cohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination

    SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.

    Time frame: From Vaccination on Day 1 through 6 Months after Vaccination [Vaccination on Day 1]

  8. Cohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination

    SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.

    Time frame: From Vaccination on Day 1 through 6 Months after Vaccination [Vaccination on Day 1]

07

Results

Posted Aug 19, 2026
Limitations and caveats
Dose strengths for vaccines have not been disclosed in the record, as per Sponsor's decision to maintain company confidentiality; the dose strengths have been denoted as low dose, medium dose and high dose.

Participant flow

There were 2 cohorts in the study: Cohort 1 enrolled participants 18 to 64 years of age and Cohort 2 enrolled participants \>=65 years of age.

Participant flow — Overall Study
MilestoneCohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo
Started515050505050505050505150505050505051505050505050505050
Vaccinated515049505050505049495150505050504950505050504950505050
Completed494949474848474848435048504548504846484949494748484948
Not completed211322322712052025211132212
Withdrew: Lost to follow-up200021320502041013100011112
Withdrew: Withdrawal by subject010301000100010000000010000
Withdrew: Other: unspecified000000001010001000111100100
Withdrew: Death000000000000000001000001000
Withdrew: Randomized but not vaccinated001000001100000011000010000

Outcome measures

PrimaryCohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination

Local reactions included redness, swelling, and pain at the injection site, were recorded in the electronic dairy (e-diary) or case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination
Percentage of participantsCohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo
Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination50.0 (35.5 to 64.5)61.2 (46.2 to 74.8)65.3 (50.4 to 78.3)80.0 (66.3 to 90.0)42.0 (28.2 to 56.8)70.0 (55.4 to 82.1)74.0 (59.7 to 85.4)72.0 (57.5 to 83.8)79.6 (65.7 to 89.8)89.6 (77.3 to 96.5)78.4 (64.7 to 88.7)86.0 (73.3 to 94.2)69.4 (54.6 to 81.7)90.0 (78.2 to 96.7)
PrimaryCohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination

Local reactions included redness, swelling, and pain at the injection site, were recorded in the e-diary or CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination
Percentage of participantsCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo
Cohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination30.0 (17.9 to 44.6)42.0 (28.2 to 56.8)42.9 (28.8 to 57.8)64.0 (49.2 to 77.1)36.7 (23.4 to 51.7)58.0 (43.2 to 71.8)66.0 (51.2 to 78.8)63.3 (48.3 to 76.6)66.7 (51.6 to 79.6)60.0 (45.2 to 73.6)68.0 (53.3 to 80.5)60.0 (45.2 to 73.6)67.3 (52.5 to 80.1)
PrimaryCohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination

Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination
Percentage of participantsCohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo
Cohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination64.0 (49.2 to 77.1)57.1 (42.2 to 71.2)49.0 (34.4 to 63.7)72.0 (57.5 to 83.8)44.0 (30.0 to 58.7)68.0 (53.3 to 80.5)68.0 (53.3 to 80.5)68.0 (53.3 to 80.5)77.6 (63.4 to 88.2)70.8 (55.9 to 83.0)70.6 (56.2 to 82.5)78.0 (64.0 to 88.5)73.5 (58.9 to 85.1)76.0 (61.8 to 86.9)
PrimaryCohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination

Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination
Percentage of participantsCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo
Cohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination34.0 (21.2 to 48.8)38.0 (24.7 to 52.8)40.8 (27.0 to 55.8)62.0 (47.2 to 75.3)40.8 (27.0 to 55.8)36.0 (22.9 to 50.8)62.0 (47.2 to 75.3)49.0 (34.4 to 63.7)56.3 (41.2 to 70.5)46.0 (31.8 to 60.7)56.0 (41.3 to 70.0)46.0 (31.8 to 60.7)57.1 (42.2 to 71.2)
PrimaryCohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. Serious AE (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.

Time frame:
From Vaccination on Day 1 through 1 month after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination
Percentage of participantsCohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo
Cohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination3.9 (0.5 to 13.5)2.0 (0.1 to 10.6)6.1 (1.3 to 16.9)2.0 (0.1 to 10.6)10.0 (3.3 to 21.8)4.0 (0.5 to 13.7)8.0 (2.2 to 19.2)2.0 (0.1 to 10.6)10.2 (3.4 to 22.2)10.2 (3.4 to 22.2)5.9 (1.2 to 16.2)6.0 (1.3 to 16.5)8.0 (2.2 to 19.2)6.0 (1.3 to 16.5)
PrimaryCohort 2: Percentage of Participants Reporting AEs From Vaccination Through 1 Month After Vaccination

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.

Time frame:
From Vaccination on Day 1 through 1 month after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 2: Percentage of Participants Reporting AEs From Vaccination Through 1 Month After Vaccination
Percentage of participantsCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo
Cohort 2: Percentage of Participants Reporting AEs From Vaccination Through 1 Month After Vaccination8.0 (2.2 to 19.2)12.0 (4.5 to 24.3)12.2 (4.6 to 24.8)2.0 (0.1 to 10.6)6.0 (1.3 to 16.5)4.0 (0.5 to 13.7)6.0 (1.3 to 16.5)8.0 (2.2 to 19.2)4.1 (0.5 to 14.0)2.0 (0.1 to 10.6)4.0 (0.5 to 13.7)12.0 (4.5 to 24.3)8.0 (2.2 to 19.2)
PrimaryCohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination

SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.

Time frame:
From Vaccination on Day 1 through 6 Months after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination
Percentage of participantsCohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo
Cohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination0 (0.0 to 7.0)2.0 (0.1 to 10.6)0 (0.0 to 7.3)2.0 (0.1 to 10.6)0 (0.0 to 7.1)0 (0.0 to 7.1)0 (0.0 to 7.1)0 (0.0 to 7.1)2.0 (0.1 to 10.9)0 (0.0 to 7.3)0 (0.0 to 7.0)0 (0.0 to 7.1)0 (0.0 to 7.1)2.0 (0.1 to 10.6)
PrimaryCohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination

SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.

Time frame:
From Vaccination on Day 1 through 6 Months after Vaccination [Vaccination on Day 1]
Reported as:
Number · Percentage of participants
Cohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination
Percentage of participantsCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo
Cohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination0 (0.0 to 7.1)0 (0.0 to 7.1)6.1 (1.3 to 16.9)4.0 (0.5 to 13.7)0 (0.0 to 7.1)2.0 (0.1 to 10.6)2.0 (0.1 to 10.6)0 (0.0 to 7.1)2.0 (0.1 to 10.9)2.0 (0.1 to 10.6)0 (0.0 to 7.1)0 (0.0 to 7.1)0 (0.0 to 7.1)

Adverse events

Collected over Systematic assessment: Local reactions and systemic events were assessed from Vaccination on Day 1 to Day 7 after Vaccination; Non-systematic assessment: SAEs were assessed from Vaccination on Day 1 up to 6 months after Vaccination; other AEs were assessed from Vaccination on Day 1 up to 1 month after Vaccination; all-cause mortality: from Vaccination on Day 1 up to 6 months after Vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo0/51 (0%)0/51 (0%)34/51 (66.7%)
Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo0/50 (0%)1/50 (2%)35/50 (70%)
Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo0/49 (0%)0/49 (0%)33/49 (67.3%)
Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo0/50 (0%)1/50 (2%)43/50 (86%)
Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine0/50 (0%)0/50 (0%)26/50 (52%)
Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo0/50 (0%)0/50 (0%)39/50 (78%)
Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)41/50 (82%)
Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)40/50 (80%)
Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo0/49 (0%)1/49 (2%)42/49 (85.7%)
Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo0/49 (0%)0/49 (0%)45/49 (91.8%)
Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo0/51 (0%)0/51 (0%)40/51 (78.4%)
Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)45/50 (90%)
Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)40/50 (80%)
Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo0/50 (0%)1/50 (2%)45/50 (90%)
Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)25/50 (50%)
Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)31/50 (62%)
Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo0/49 (0%)3/49 (6.1%)29/49 (59.2%)
Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo1/50 (2%)2/50 (4%)37/50 (74%)
Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine0/50 (0%)0/50 (0%)29/50 (58%)
Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo0/50 (0%)1/50 (2%)33/50 (66%)
Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo0/50 (0%)1/50 (2%)38/50 (76%)
Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)35/50 (70%)
Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo0/49 (0%)1/49 (2%)39/49 (79.6%)
Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo1/50 (2%)1/50 (2%)35/50 (70%)
Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo0/50 (0%)0/50 (0%)39/50 (78%)
Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)30/50 (60%)
Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo0/50 (0%)0/50 (0%)36/50 (72%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventCohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo
Chest painGeneral disorders0/510/500/490/500/500/500/500/501/490/490/510/500/500/500/500/500/490/500/500/500/500/500/490/500/500/500/50
BacteraemiaInfections and infestations0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/500/490/500/500/500/500/501/490/500/500/500/50
Escherichia pyelonephritisInfections and infestations0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/500/490/500/500/500/500/501/490/500/500/500/50
PneumoniaInfections and infestations0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/501/490/500/500/500/500/500/490/500/500/500/50
SepsisInfections and infestations0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/500/490/500/500/500/500/501/490/500/500/500/50
Femoral neck fractureInjury, poisoning and procedural complications0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/501/490/500/500/500/500/500/490/500/500/500/50
Lumbar radiculopathyNervous system disorders0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/501/490/500/500/500/500/500/490/500/500/500/50
Acute kidney injuryRenal and urinary disorders0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/500/490/500/500/500/500/501/490/500/500/500/50
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/501/490/500/500/500/500/500/490/500/500/500/50
Coronary artery diseaseCardiac disorders0/510/500/490/500/500/500/500/500/490/490/510/500/500/500/500/500/490/500/501/500/500/500/490/500/500/500/50
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo
Injection site pain (PAIN)General disorders25/5130/5032/4940/5020/5035/5036/5036/5039/4943/4940/5143/5034/5044/5015/5021/5020/4931/5016/5028/5033/5029/5030/4930/5033/5029/5033/50
Fatigue (FATIGUE)General disorders24/5122/5019/4930/5018/5028/5029/5027/5037/4929/4929/5136/5028/5033/5010/508/507/4922/5013/5013/5019/5018/5021/4910/5023/5014/5019/50
Headache (HEADACHE)Nervous system disorders22/5117/5013/4925/5012/5020/5022/5021/5025/4921/4926/5128/5020/5025/507/5011/5011/4912/5014/5012/5017/5010/5012/4911/5012/5014/5018/50
Chills (CHILLS)General disorders7/517/507/4914/509/5019/5023/5016/5019/4923/4917/5124/5019/5024/505/504/502/499/504/5010/5012/508/509/496/5011/5010/5012/50
Myalgia (MUSCLEPAIN)Musculoskeletal and connective tissue disorders10/519/506/4918/507/5015/5018/5010/5021/4913/4919/5118/5016/5019/506/507/507/496/506/509/5014/506/5010/4911/5014/5012/5014/50
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders4/514/507/4913/505/5010/5013/504/5010/499/4914/5112/509/5013/505/507/505/495/504/506/509/503/504/496/507/506/509/50
Injection site swelling (SWELLING)General disorders3/512/501/492/501/503/506/505/506/4911/494/515/504/507/503/501/503/492/504/504/501/506/506/494/505/509/506/50
Pyrexia (FEVER)General disorders1/511/501/491/501/505/503/504/509/493/496/515/509/508/502/501/501/493/500/502/503/501/501/490/505/502/504/50
Diarrhoea (DIARRHEA)Gastrointestinal disorders6/517/503/493/505/503/508/508/507/496/494/516/505/504/505/502/502/492/505/503/500/504/507/491/502/506/504/50
Injection site erythema (REDNESS)General disorders1/515/500/492/502/503/503/505/502/496/494/517/504/507/501/501/501/494/503/503/500/501/502/494/505/507/504/50

Baseline characteristics

Baseline analysis population was evaluated on safety population which included all participants who received any study intervention.

Age, Customized
Age, Customized(Participants)Cohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboTotal
18-64 years51504950505050504949515050500000000000000699
>=65 years0000000000000050504950505050504950505050648
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboTotal
Female312525272929272929233425283120313128282131312316243223731
Male202524232121232120261725221930191822222919192634261827616
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboTotal
Hispanic or Latino121614101712181814131611201720201917161819182022262424471
Not Hispanic or Latino383435383337313035363539293330303032343231312928242525864
Unknown or Not Reported10020112000010000100010001112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1, Arm A: Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm B: Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm C: High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm D: Low Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 VaccineCohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm J: High Dose Investigational Influenza Vaccine + PlaceboCohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +PlaceboCohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm AA: Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm BB: Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm CC: High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 VaccineCohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboCohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + PlaceboCohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + PlaceboCohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+PlaceboCohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + PlaceboCohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + PlaceboTotal
American Indian or Alaska Native0000000000100001000000000103
Asian54581444126433021020232311172
Native Hawaiian or Other Pacific Islander0000010000000000000000100103
Black or African American12151211191512991317141491113111661491091171310321
White313032302929333537332728323838343734403539353736423439924
More than one race20011101110410100021010000018
Unknown or Not Reported1100001110000000000001000006
08

Study locations

22 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Miami Dade Medical Research Institute, LLC
    Miami, Florida 33176, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014, United States
  • Headlands Research Orlando
    Orlando, Florida 32819, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center
    Springfield, Missouri 65807, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Las Vegas Clinical Trials
    Las Vegas, Nevada 89030, United States
  • ActivMed Practices & Research, LLC.
    Portsmouth, New Hampshire 03801, United States
  • DM Clinical Research- Cyfair
    Houston, Texas 77065, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    Tomball, Texas 77375, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jul 2025, 8 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 12, 2024
StartActual
Nov 11, 2024
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 15, 2025
Results first posted
Aug 19, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06683352
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Nov 11, 2024
Primary completion
Jul 15, 2025
Completion
Jul 15, 2025
Results posted
Aug 19, 2026
Last update
Aug 19, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion